Gene editing company announces $73.9m Series C financing
Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS). The proceeds will support clinical development of the company’s lead therapeutic candidate,… Read More